Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Aquestive Therapeutics, Inc.

AQSTNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Sep 9, 2026Accepted Sep 9, 2026, 4:20 PM EDTFiling CIK 2026090Accession 0001950047-26-009243
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Aquestive Therapeutics, Inc.
Issuer CIK
0001398733
SEC file number
001-38599
Phone
9089411900
Person for whose account securities are to be sold
Sherry M. Korczynski
Relationships to issuer
Officer
Street
30 Technology Drive
City
Warren
State / country code
NJ
Postal code
07059

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common8,75045,587.50125,511,64809/09/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common09/09/2026Exercise of Stock OptionsIssuer8,750N09/09/2026Cash

Prior-sale reporting

Nothing to report for the preceding three months
Y

Notice signature

Notice date
09/09/2026
Signed
/s/ Sherry M. Korczynski
Plan adoption dates
06/10/2026

Company context

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions, including alopecia areata.

Current securities

Recent company filings

  1. 4 filingNov 16, 2026
  2. Regulation FD DisclosureNov 16, 2026
  3. Regulation FD DisclosureNov 5, 2026
  4. 10-Q filingNov 3, 2026
  5. Results of Operations and Financial Condition · Regulation FD DisclosureNov 3, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.